22q11.2 Deletion Syndrome Clinical Trial
Official title:
Genetic Modifiers for 22q11.2 Syndrome
The purpose of the project is the determination of how the deletion of DNA from chromosome 22 at the q11.2 band causes the phenotypes observed in velo-cardio-facial syndrome (VCFS). In other words, the purpose remains genotype-to-phenotype matching. Current methods includes the use of whole genome chips and microarray analysis. Blood samples are collected for DNA from every patient who consents from the VCFS Center at Upstate Medical University. They are examined for phenotypic features consistent with our typical clinical evaluation. The information from these examinations will be entered anonymously into a database. Genomic information is then matched to clinical phenotype with appropriate statistical method applied.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04639960 -
Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome
|
N/A | |
| Recruiting |
NCT04373226 -
Arithmetic Abilities in Children With 22q11.2DS
|
N/A | |
| Completed |
NCT01781923 -
Cognitive Remediation in 22q11DS
|
N/A | |
| Terminated |
NCT03284060 -
Social Cognition Training and Cognitive Remediation
|
N/A | |
| Completed |
NCT02895906 -
Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions
|
Phase 1 | |
| Recruiting |
NCT04639388 -
Understanding of Psychotic Disorders in Children With 22q11.2DS
|
N/A | |
| Recruiting |
NCT05924347 -
Early Scoliotic Changes in Children at Increased Risk for Scoliosis Development
|
||
| Recruiting |
NCT00556530 -
Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome
|
||
| Completed |
NCT02460328 -
Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome
|
N/A | |
| Completed |
NCT04647500 -
Effects of Methylphenidate on Brain and Cognition in 22q11 Deletion Syndrome
|
N/A |